{"protocolSection":{"identificationModule":{"nctId":"NCT00312728","orgStudyIdInfo":{"id":"AVF3752g"},"organization":{"fullName":"Genentech, Inc.","class":"INDUSTRY"},"briefTitle":"A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)","officialTitle":"A Phase II Trial of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2022-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2009-06","type":"ACTUAL"},"completionDateStruct":{"date":"2009-06","type":"ACTUAL"},"studyFirstSubmitDate":"2006-04-07","studyFirstSubmitQcDate":"2006-04-07","studyFirstPostDateStruct":{"date":"2006-04-11","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-03-18","resultsFirstSubmitQcDate":"2011-05-25","resultsFirstPostDateStruct":{"date":"2011-06-22","type":"ESTIMATED"},"lastUpdateSubmitDate":"2022-12-09","lastUpdatePostDateStruct":{"date":"2023-01-06","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Genentech, Inc.","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This was an open-label, multicenter, single-arm, Phase II trial of bevacizumab combined with first- or second-line therapy in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with previously treated central nervous system (CNS) metastases. A total of 115 patients enrolled in the study."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer","Brain Neoplasms"],"keywords":["Brain Cancer","Brain Metastases","Avastin","NSCLC","Lung Cancer","PASSPORT"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":115,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"bevacizumab","type":"EXPERIMENTAL","interventionNames":["Drug: bevacizumab","Drug: First-Line Chemotherapy Agents","Drug: Second-Line Chemotherapy Agents"]}],"interventions":[{"type":"DRUG","name":"bevacizumab","description":"15 mg/kg intravenously (IV) on the first day of each 21- to 28-day cycle (± 4 days); the interval between infusions could not be \\< 17 days, but could extend beyond 28 days if chemotherapy was delayed to allow recovery from toxicity.","armGroupLabels":["bevacizumab"],"otherNames":["Avastin"]},{"type":"DRUG","name":"First-Line Chemotherapy Agents","description":"Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was administered on Days 1 and 8 of every cycle. Agents were administered as a platinum doublet, or erlotinib alone, at the investigator's discretion. Chemotherapy was administered for a total of 6 planned cycles (up to 8 cycles with prior approval from the Medical Monitor), followed by single-agent bevacizumab therapy. The chemotherapy regimen was to be consistent throughout the study. Erlotinib was administered orally daily.\n\nAll agents were dosed and administered per institutional standards using the respective package insert as a guideline.","armGroupLabels":["bevacizumab"]},{"type":"DRUG","name":"Second-Line Chemotherapy Agents","description":"Erlotinib, pemetrexed, docetaxel, or chemotherapy at the investigator's discretion. Erlotinib was administered orally daily; pemetrexed and docetaxel were administered IV on Day 1 of every 21-day cycle. Single-agent bevacizumab therapy could be continued at the investigator's discretion if the second-line agent was discontinued.\n\nAll agents were dosed and administered per institutional standards using the respective package insert as a guideline.","armGroupLabels":["bevacizumab"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Symptomatic National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0 (NCI CTCAE) Grade ≥2 Central Nervous System (CNS) Hemorrhage","description":"The percentage of participants with symptomatic NCI CTCAE Grade ≥ 2 CNS hemorrhage, defined as the presence of clinical symptoms determined by the investigator to be directly referable to a Grade ≥ 2 CNS hemorrhage.\n\nGrade 1: Asymptomatic, radiographic findings only Grade 2: Medical intervention indicated Grade 3: Ventriculostomy, intracranial pressure (ICP) monitoring, intraventricular thrombolysis, or operative intervention indicated Grade 4: Life-threatening consequences; neurologic deficit or disability Grade 5: Death","timeFrame":"From the first administration of bevacizumab until 60 days after discontinuation of bevacizumab treatment was reported (up to 2 years)"}],"secondaryOutcomes":[{"measure":"Overall Survival (OS) in First-line Setting","description":"To assess overall survival in the subset of subjects treated in the first-line setting with bevacizumab plus either chemotherapy or erlotinib for non-squamous NSCLC with previously treated brain metastases.","timeFrame":"Time from enrollment to death from any cause (up to 2 years)"},{"measure":"Number of Participants With Overall Survival (OS) in First-line Setting [1-Year or More Survival]","description":"Number of Participants with overall survival in the subset of subjects treated in the first-line setting with bevacizumab plus either chemotherapy or erlotinib for non-squamous NSCLC with previously treated brain metastases.","timeFrame":"Time from enrollment to death from any cause (up to 2 years)"},{"measure":"OS in First-line and Second-line Settings","description":"To assess overall survival in the subset of subjects treated in the first-line setting with bevacizumab plus either chemotherapy or erlotinib for non-squamous NSCLC with previously treated brain metastases.","timeFrame":"Time from enrollment to death from any cause (up to 2 years)"},{"measure":"Number of Participants With OS in First-line and Second-line Settings [1-Year or More Survival]","description":"To assess the number of participants with overall survival in the subset of subjects treated in the first-line setting with bevacizumab plus either chemotherapy or erlotinib for non-squamous NSCLC with previously treated brain metastases.","timeFrame":"Time from enrollment to death from any cause (up to 2 years)"},{"measure":"Number of Participants With Selected Adverse Events","description":"Number of participants with selected adverse events (all grades based on NCI CTCAE) included any grade CNS hemorrhage, any grade pulmonary hemorrhage, any grade gastrointestinal (GI) perforation, Grade ≥ 2 arterial thromboembolic event, Grade ≥ 2 left ventricular systolic dysfunction, Grade ≥ 3 non-CNS non-pulmonary hemorrhage, Grade ≥ 3 proteinuria, Grade ≥ 3 proteinuria, Grade ≥ 3 hypertension, any serious adverse event\\*, and any adverse event leading to study treatment discontinuation.\n\n\\*For serious adverse events, please see Adverse Event Reporting Section.","timeFrame":"From start of bevacizumab treatment to 60 days following discontinuation of bevacizumab (up to 2 years)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed informed consent\n* Histologically or cytologically confirmed NSCLC except for squamous cell carcinoma\n* Treated brain metastases without evidence of progression or hemorrhage after treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period\n* Appropriateness for first- or second-line systemic therapy for advanced NSCLC\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Age ≥ 18 years\n* For women of childbearing potential and sexually active males, use of an accepted and effective method of contraception (e.g., hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study\n\nExclusion Criteria:\n\n* Brain biopsy/neurosurgical procedure performed within 3 months prior to Day 1\n* Progressive neurologic symptoms\n* Active malignancy other than lung cancer\n* Current, recent, or planned participation in an experimental drug study\n* Prior treatment with an investigational or marketed agent that acts by anti-angiogenesis mechanisms\n* Gross hemoptysis within 3 months prior to Day 1\n* Inadequately controlled hypertension\n* Unstable angina or New York Heart Association Grade II or greater congestive heart failure (CHF)\n* Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1\n* Myocardial infarction within 6 months prior to Day 1\n* Stroke within 6 months prior to Day 1\n* Active symptomatic peripheral vascular disease within 6 months prior to Day 1\n* History of significant vascular disease\n* Evidence of bleeding diathesis or coagulopathy\n* Known hypersensitivity to any components of bevacizumab\n* Inadequate organ function\n* Serious non-healing wound, ulcer, or bone fracture\n* Urine protein/creatinine (UPC) ratio of ≥ 1.0\n* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1, or anticipation of need for major surgical procedure during the course of the study\n* Pregnancy or lactation\n* Known evidence of disseminated intravascular coagulation (DIC)\n* Active infection or fever \\> 38.5°C within 3 days prior to Day 1\n* Any other medical condition (including mental illness or substance abuse) deemed by the clinician to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"David Karlin, M.D.","affiliation":"Genentech, Inc.","role":"STUDY_DIRECTOR"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"This was an open-label, multicenter, single-arm, Phase II trial of bevacizumab combined with first- or second-line therapy in subjects with metastatic non-squamous non-small cell lung cancer (NSCLC) with previously treated CNS metastases.","recruitmentDetails":"Approximately 110 subjects were to be enrolled at approximately 40 sites to obtain 100 bevacizumab-treated evaluable subjects. Study started 28 NOV 2005 and completed 5 JUN 2009.","groups":[{"id":"FG000","title":"Bevacizumab","description":"15 mg/kg IV on the first day of each 21- to 28-day cycle (+/-4 days) in combination with first or second-line therapy"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"115"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"110"}]}],"dropWithdraws":[{"type":"Progressive disease","reasons":[{"groupId":"FG000","numSubjects":"53"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"32"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"10"}]},{"type":"Required non-protocol cancer treatment","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"10"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Bevacizumab","description":"15 mg/kg IV on the first day of each 21- to 28-day cycle (+/-4 days) in combination with first or second-line therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"115"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"58","spread":"10.6"}]}]}]},{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"patients","classes":[{"title":"18-40 years","categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}]},{"title":"41-64 years","categories":[{"measurements":[{"groupId":"BG000","value":"77"}]}]},{"title":">=65 years","categories":[{"measurements":[{"groupId":"BG000","value":"32"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"53"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"62"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Symptomatic National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0 (NCI CTCAE) Grade ≥2 Central Nervous System (CNS) Hemorrhage","description":"The percentage of participants with symptomatic NCI CTCAE Grade ≥ 2 CNS hemorrhage, defined as the presence of clinical symptoms determined by the investigator to be directly referable to a Grade ≥ 2 CNS hemorrhage.\n\nGrade 1: Asymptomatic, radiographic findings only Grade 2: Medical intervention indicated Grade 3: Ventriculostomy, intracranial pressure (ICP) monitoring, intraventricular thrombolysis, or operative intervention indicated Grade 4: Life-threatening consequences; neurologic deficit or disability Grade 5: Death","populationDescription":"The safety-evaluable population consisted of all patients who received at least one dose of bevacizumab.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"90% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From the first administration of bevacizumab until 60 days after discontinuation of bevacizumab treatment was reported (up to 2 years)","groups":[{"id":"OG000","title":"Bevacizumab","description":"15 mg/kg IV on the first day of each 21- to 28-day cycle (+/-4 days) in combination with first or second-line therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"2.5"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) in First-line Setting","description":"To assess overall survival in the subset of subjects treated in the first-line setting with bevacizumab plus either chemotherapy or erlotinib for non-squamous NSCLC with previously treated brain metastases.","populationDescription":"The first-line efficacy-evaluable population consisted of 70 patients who received at least one dose of bevacizumab.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Time from enrollment to death from any cause (up to 2 years)","groups":[{"id":"OG000","title":"Bevacizumab","description":"15 mg/kg IV on the first day of each 21- to 28-day cycle (+/-4 days) in combination with first or second-line therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","lowerLimit":"9.6","upperLimit":"13.9"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Overall Survival (OS) in First-line Setting [1-Year or More Survival]","description":"Number of Participants with overall survival in the subset of subjects treated in the first-line setting with bevacizumab plus either chemotherapy or erlotinib for non-squamous NSCLC with previously treated brain metastases.","populationDescription":"The first-line efficacy-evaluable population consisted of 70 patients who received at least one dose of bevacizumab.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Time from enrollment to death from any cause (up to 2 years)","groups":[{"id":"OG000","title":"Bevacizumab","description":"15 mg/kg IV on the first day of each 21- to 28-day cycle (+/-4 days) in combination with first or second-line therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}]}]},{"type":"SECONDARY","title":"OS in First-line and Second-line Settings","description":"To assess overall survival in the subset of subjects treated in the first-line setting with bevacizumab plus either chemotherapy or erlotinib for non-squamous NSCLC with previously treated brain metastases.","populationDescription":"The efficacy-evaluable population consisted of all patients who received at least one dose of bevacizumab.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Time from enrollment to death from any cause (up to 2 years)","groups":[{"id":"OG000","title":"Bevacizumab","description":"15 mg/kg IV on the first day of each 21- to 28-day cycle (+/-4 days) in combination with first or second-line therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","lowerLimit":"10.3","upperLimit":"14.9"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With OS in First-line and Second-line Settings [1-Year or More Survival]","description":"To assess the number of participants with overall survival in the subset of subjects treated in the first-line setting with bevacizumab plus either chemotherapy or erlotinib for non-squamous NSCLC with previously treated brain metastases.","populationDescription":"The efficacy-evaluable population consisted of all patients who received at least one dose of bevacizumab.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Time from enrollment to death from any cause (up to 2 years)","groups":[{"id":"OG000","title":"Bevacizumab","description":"15 mg/kg IV on the first day of each 21- to 28-day cycle (+/-4 days) in combination with first or second-line therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Selected Adverse Events","description":"Number of participants with selected adverse events (all grades based on NCI CTCAE) included any grade CNS hemorrhage, any grade pulmonary hemorrhage, any grade gastrointestinal (GI) perforation, Grade ≥ 2 arterial thromboembolic event, Grade ≥ 2 left ventricular systolic dysfunction, Grade ≥ 3 non-CNS non-pulmonary hemorrhage, Grade ≥ 3 proteinuria, Grade ≥ 3 proteinuria, Grade ≥ 3 hypertension, any serious adverse event\\*, and any adverse event leading to study treatment discontinuation.\n\n\\*For serious adverse events, please see Adverse Event Reporting Section.","populationDescription":"The safety-evaluable population consisted of all patients who received at least one dose of bevacizumab.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"From start of bevacizumab treatment to 60 days following discontinuation of bevacizumab (up to 2 years)","groups":[{"id":"OG000","title":"Bevacizumab","description":"15 mg/kg IV on the first day of each 21- to 28-day cycle (+/-4 days) in combination with first or second-line therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"}]}],"classes":[{"title":"Any grade CNS hemorrhage","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Any grade pulmonary hemorrhage","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Grade ≥ 2 arterial thromboembolic event","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Grade ≥ 3 non-CNS non-pulmonary hemorrhage","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Grade ≥ 3 venous thromboembolic event","categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]},{"title":"Any grade gastrointestinal perforation","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Grade ≥ 3 hypertension","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Grade ≥ 3 proteinuria","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Grade ≥ 2 left ventricular systolic dysfunction","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Reversible Posterior Leukoencephalopathy Syndrome","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Any event leading to treatment discontinuation","categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From start of bevacizumab treatment to 60 days following discontinuation of bevacizumab (up to 2 years).","eventGroups":[{"id":"EG000","title":"Bevacizumab","description":"15 mg/kg IV on the first day of each 21- to 28-day cycle (+/-4 days) in combination with first or second-line therapy","seriousNumAffected":45,"seriousNumAtRisk":106,"otherNumAffected":7,"otherNumAtRisk":106}],"seriousEvents":[{"term":"Pulmonary Embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":106}]},{"term":"Pulmonary Hemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":106}]},{"term":"Chronic Obstructive Pulmonary Disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Hemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Respiratory Distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Respiratory Failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":106}]},{"term":"Ataxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"BRAIN OEDEMA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Cerebral Arteriosclerosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Leukoencephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Transient Ischemic Attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":106}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":106}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Lobar Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Perirectal Abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Rectal Abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Gastrointestinal Hemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":106}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Gastroesophageal Reflux Disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Small Intestinal Obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":106}]},{"term":"Febrile Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Chest Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":106}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":106}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Failure to Thrive","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Hip Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Spinal Compression Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Mental Status Changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":106}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Orthostatic Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Venous Thrombosis Limb","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Hypoaldosteronism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Muscular Weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Lung Neoplasm Malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]},{"term":"Renal Failure Acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":106}]}],"otherEvents":[{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":106}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffman-LaRoche","phone":"800-821-8590"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["United States"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D001932","term":"Brain Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D016543","term":"Central Nervous System Neoplasms"},{"id":"D009423","term":"Nervous System Neoplasms"},{"id":"D001927","term":"Brain Diseases"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068258","term":"Bevacizumab"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"}]}},"hasResults":true}